Medical Devices
-
Legacy of Medical Device Leadership
For over three decades, Wilson Sonsini has been the trusted legal partner to pioneering medical device companies—guiding them from formation through IPO and strategic partnerships across their entire business life cycle. Through the seamless integration of this practice, we leverage this deep institutional knowledge to continue guiding the next generation of trailblazers.
-
Ranked No. 1 by PitchBook
Wilson Sonsini was ranked No. 1 by PitchBook based on the number of medical devices and supplies venture financings. (PitchBook 2025)
-
$8.8 Billion in VC Deals
Over the last 5 years, Wilson Sonsini has counseled over 260 medical device companies in venture financing deals, totaling over $8.8 billion in capital invested. (PitchBook 2021-2026)
-
$6.6 Billion in M&A Deals
We advised our medical device clients in 40+ M&A transactions, totaling over $6.6 billion in capital invested. (Capital IQ 2021-2026)
One of the driving forces behind the life sciences practice at Wilson Sonsini Goodrich & Rosati is its representation of medical device manufacturers and successful medical device entrepreneurs and investors. Wilson Sonsini's experience in the sector dates back to the industry's formative years, when exciting new companies first began to invent, develop, and commercialize breakthrough medical technologies.
A substantial number of the practitioners in the firm's medical device practice—including attorneys, patent agents, and scientific advisors—have advanced degrees in biology, chemistry, engineering, or other scientific fields. Similarly, a large number of our professionals have experience working in laboratory, medical, or research facilities. The team also includes attorneys who have served as in-house legal counsel for major life sciences companies.
Wilson Sonsini has consistently represented medical technology companies at all stages, from formation to exit. Our work with emerging medical device companies is typically focused on areas that are vital to early-stage enterprises, particularly intellectual property and finance. Those and other services we commonly provide are explained in the above tabs.
One of the driving forces behind the life sciences practice at Wilson Sonsini Goodrich & Rosati is its representation of medical device manufacturers and successful medical device entrepreneurs and investors. Wilson Sonsini's experience in the sector dates back to the industry's formative years, when exciting new companies first began to invent, develop, and commercialize breakthrough medical technologies.
A substantial number of the practitioners in the firm's medical device practice—including attorneys, patent agents, and scientific advisors—have advanced degrees in biology, chemistry, engineering, or other scientific fields. Similarly, a large number of our professionals have experience working in laboratory, medical, or research facilities. The team also includes attorneys who have served as in-house legal counsel for major life sciences companies.
Wilson Sonsini has consistently represented medical technology companies at all stages, from formation to exit. Our work with emerging medical device companies is typically focused on areas that are vital to early-stage enterprises, particularly intellectual property and finance. Those and other services we commonly provide are explained in the above tabs.
Wilson Sonsini offers medical device clients the benefit of working with the highly skilled IP professionals in our patent and innovations counseling practice. In addition to advising on strategic matters, this team handles a significant number of patent filings.
Wilson Sonsini was named Life Sciences IP Firm of the Year at the inaugural LSPN Awards USA 2025, selected by an independent panel from 12 law firm nominees. The award specifically honors excellence in medtech, biotech, and pharmaceutical patent protection. The firm was also named a finalist for Life Sciences Patent Strategy Firm of the Year and Life Sciences IP Litigation Firm of the Year at the same ceremony. Building on that recognition, in February 2026 Wilson Sonsini was named a finalist in two categories at the LSPN Awards USA 2026: Life Sciences IP Firm of the Year and Life Sciences IP Litigation Firm of the Year.
Wilson Sonsini offers medical device clients the benefit of working with the highly skilled IP professionals in our patent and innovations counseling practice. In addition to advising on strategic matters, this team handles a significant number of patent filings.
Wilson Sonsini was named Life Sciences IP Firm of the Year at the inaugural LSPN Awards USA 2025, selected by an independent panel from 12 law firm nominees. The award specifically honors excellence in medtech, biotech, and pharmaceutical patent protection. The firm was also named a finalist for Life Sciences Patent Strategy Firm of the Year and Life Sciences IP Litigation Firm of the Year at the same ceremony. Building on that recognition, in February 2026 Wilson Sonsini was named a finalist in two categories at the LSPN Awards USA 2026: Life Sciences IP Firm of the Year and Life Sciences IP Litigation Firm of the Year.
Wilson Sonsini consistently represents more companies that receive venture financing than any other U.S. law firm and was ranked No. 1 for the most venture capital and private equity deals in 2025 by LSEG, across all industries in the U.S. (LSEG Global Legal Private Equity and Venture Capital Review, 2025)
One reason for the firm’s venture financing leadership is the long-standing relationships we have built working alongside innovative entrepreneurs to launch successful medical device companies. Another key driver of our success is our experience working with influential sources of funding: The firm represents more than 100 venture capital and private equity firms.
Wilson Sonsini holds a Band 1 ranking for Venture Capital in the 2025 Chambers USA guide and was named a finalist for Venture Capital Firm of the Year in the 2025 LMG Life Sciences Awards.
Wilson Sonsini consistently represents more companies that receive venture financing than any other U.S. law firm and was ranked No. 1 for the most venture capital and private equity deals in 2025 by LSEG, across all industries in the U.S. (LSEG Global Legal Private Equity and Venture Capital Review, 2025)
One reason for the firm’s venture financing leadership is the long-standing relationships we have built working alongside innovative entrepreneurs to launch successful medical device companies. Another key driver of our success is our experience working with influential sources of funding: The firm represents more than 100 venture capital and private equity firms.
Wilson Sonsini holds a Band 1 ranking for Venture Capital in the 2025 Chambers USA guide and was named a finalist for Venture Capital Firm of the Year in the 2025 LMG Life Sciences Awards.
Wilson Sonsini advises maturing medical device companies as they reach important developmental milestones. Dating back to some of the most significant, landmark collaborations and partnering deals between industry pioneers, Wilson Sonsini’s attorneys have helped medical technology clients structure and execute all manner of sophisticated, strategic transactions, working closely with each client to leverage their valuable intellectual property assets to achieve diverse market objectives.
The firm advises life sciences companies on the structure of hundreds of corporate collaborations. Our experience includes developing, negotiating, and implementing:
- Co-branding and promotional agreements
- Cross-border agreements
- Research and development agreements
- Strategic alliances
- Joint development agreements
- Co-investment agreements
- Joint marketing agreements
In addition, our team has vast experience with a broad range of joint venture transactions involving medical device clients. We have also recently introduced clients to novel, creative agreements—such as build-to-buy agreements—aimed at benefiting multiple parties.
Wilson Sonsini advises maturing medical device companies as they reach important developmental milestones. Dating back to some of the most significant, landmark collaborations and partnering deals between industry pioneers, Wilson Sonsini’s attorneys have helped medical technology clients structure and execute all manner of sophisticated, strategic transactions, working closely with each client to leverage their valuable intellectual property assets to achieve diverse market objectives.
The firm advises life sciences companies on the structure of hundreds of corporate collaborations. Our experience includes developing, negotiating, and implementing:
- Co-branding and promotional agreements
- Cross-border agreements
- Research and development agreements
- Strategic alliances
- Joint development agreements
- Co-investment agreements
- Joint marketing agreements
In addition, our team has vast experience with a broad range of joint venture transactions involving medical device clients. We have also recently introduced clients to novel, creative agreements—such as build-to-buy agreements—aimed at benefiting multiple parties.
Regulatory approvals are critically important to growing medical device companies. Wilson Sonsini has a dedicated regulatory team that helps place medical device clients in a favorable position to clear regulatory hurdles and secure timely approvals. Our team also helps such clients remain in compliance with strictly enforced regulatory laws in the U.S. and international markets.
Regulatory approvals are critically important to growing medical device companies. Wilson Sonsini has a dedicated regulatory team that helps place medical device clients in a favorable position to clear regulatory hurdles and secure timely approvals. Our team also helps such clients remain in compliance with strictly enforced regulatory laws in the U.S. and international markets.
Many of Wilson Sonsini's successful medical device clients have opted to enter the capital markets, most often through an initial public offering. We are consistently ranked by Bloomberg, Thomson Reuters, and CapitalIQ as a leading advisor to companies and underwriters based on the number of completed IPOs and equity and equity-linked offerings. Over the past 20 years, the firm has represented some of the world’s most iconic companies, including Google, LinkedIn, and Lyft.
Wilson Sonsini has advised numerous medical device clients on their IPOs, including SpyGlass Pharma, Concord Healthcare, ScienTech Medical, Ra Medical, and Establishment Labs. The firm has also represented medical device and equipment companies in several follow-on public offerings.
Many of Wilson Sonsini's successful medical device clients have opted to enter the capital markets, most often through an initial public offering. We are consistently ranked by Bloomberg, Thomson Reuters, and CapitalIQ as a leading advisor to companies and underwriters based on the number of completed IPOs and equity and equity-linked offerings. Over the past 20 years, the firm has represented some of the world’s most iconic companies, including Google, LinkedIn, and Lyft.
Wilson Sonsini has advised numerous medical device clients on their IPOs, including SpyGlass Pharma, Concord Healthcare, ScienTech Medical, Ra Medical, and Establishment Labs. The firm has also represented medical device and equipment companies in several follow-on public offerings.
An acquisition can often be an ideal exit strategy for a medical device company, because it can signal the continued viability of a developing product line, as well as broader, even global distribution options that may not have otherwise been available to the company. Wilson Sonsini has represented scores of medical device and equipment clients that reached a point in their development where either selling part or all of the company proved to be the best strategic option.
Wilson Sonsini is consistently ranked among the top firms worldwide, based on the number of M&A deals and deal volume, including the most recent year-end rankings issued by LSEG.
The firm's strength in this space continues to be recognized. On May 4, 2026, Mergers & Acquisitions named the winners of its Middle-Market Deals of the Year award; two deals led by Wilson Sonsini received honorable mentions. The first, Transcarent's acquisition of Accolade—with a total equity value of approximately $861 million—represents a significant advancement in AI application within the healthcare sector; Wilson Sonsini advised Transcarent on the transaction. The second, Boston Scientific's acquisition of Bolt Medical, is expected to enhance Boston Scientific's cardiovascular portfolio and advance the company's strategy to address coronary and peripheral disease; Wilson Sonsini advised Bolt Medical on the transaction. For more information, see our client highlights about the Transcarent and Bolt Medical deals, or visit the Mergers & Acquisitions site to view the complete list.
While Wilson Sonsini has represented medical device clients in hundreds of smaller M&A transactions and limited intellectual property asset acquisitions, the firm has also been involved in some of the largest M&A deals in the life sciences industry. For example, Wilson Sonsini represented Pharmacyclics in its sale to AbbVie for approximately $21 billion.
An acquisition can often be an ideal exit strategy for a medical device company, because it can signal the continued viability of a developing product line, as well as broader, even global distribution options that may not have otherwise been available to the company. Wilson Sonsini has represented scores of medical device and equipment clients that reached a point in their development where either selling part or all of the company proved to be the best strategic option.
Wilson Sonsini is consistently ranked among the top firms worldwide, based on the number of M&A deals and deal volume, including the most recent year-end rankings issued by LSEG.
The firm's strength in this space continues to be recognized. On May 4, 2026, Mergers & Acquisitions named the winners of its Middle-Market Deals of the Year award; two deals led by Wilson Sonsini received honorable mentions. The first, Transcarent's acquisition of Accolade—with a total equity value of approximately $861 million—represents a significant advancement in AI application within the healthcare sector; Wilson Sonsini advised Transcarent on the transaction. The second, Boston Scientific's acquisition of Bolt Medical, is expected to enhance Boston Scientific's cardiovascular portfolio and advance the company's strategy to address coronary and peripheral disease; Wilson Sonsini advised Bolt Medical on the transaction. For more information, see our client highlights about the Transcarent and Bolt Medical deals, or visit the Mergers & Acquisitions site to view the complete list.
While Wilson Sonsini has represented medical device clients in hundreds of smaller M&A transactions and limited intellectual property asset acquisitions, the firm has also been involved in some of the largest M&A deals in the life sciences industry. For example, Wilson Sonsini represented Pharmacyclics in its sale to AbbVie for approximately $21 billion.
As medical device and equipment manufacturers grow, they often become involved in a proportionately larger number of business disputes. Our attorneys have successfully represented medical device companies engaged in litigation with competitors, suppliers, service providers, employees, and other entities, with disputes ranging from employment-related lawsuits to high-stakes patent litigation.
We have also successfully defended medical device and equipment companies in class actions, including antitrust, consumer, and securities litigation matters. In addition to representing companies in federal and state courts throughout the U.S., our attorneys represent companies in arbitrations and mediations.
As medical device and equipment manufacturers grow, they often become involved in a proportionately larger number of business disputes. Our attorneys have successfully represented medical device companies engaged in litigation with competitors, suppliers, service providers, employees, and other entities, with disputes ranging from employment-related lawsuits to high-stakes patent litigation.
We have also successfully defended medical device and equipment companies in class actions, including antitrust, consumer, and securities litigation matters. In addition to representing companies in federal and state courts throughout the U.S., our attorneys represent companies in arbitrations and mediations.
- Privacy Policy
- Terms of Use
- Accessibility